Tissue-type plasminogen activator in plasma from breast cancer patients determined by enzyme-linked immunosorbent assay
1990

Measuring Tissue-Type Plasminogen Activator in Breast Cancer Patients

Sample size: 126 publication Evidence: moderate

Author Information

Author(s): J. Gr0ndahl-Hansen, F. Bach, P. Munkholm-Larsen

Primary Institution: Technical University of Denmark

Hypothesis

Is there a difference in tissue-type plasminogen activator (t-PA) levels in plasma between healthy individuals and breast cancer patients?

Conclusion

Breast cancer patients have significantly higher levels of t-PA in their plasma compared to healthy donors, and this increase correlates with the extent of disease.

Supporting Evidence

  • The mean t-PA concentration in healthy donors was 2.4 ng/ml, while in breast cancer patients it was 5.3 ng/ml.
  • 40% of breast cancer patients had t-PA levels above the cut-off point of 5.0 ng/ml.
  • 90% of patients with massive tumor burden had elevated t-PA levels.

Takeaway

Doctors found that breast cancer patients have more of a certain protein in their blood than healthy people, which might help them understand how serious the cancer is.

Methodology

An enzyme-linked immunosorbent assay (ELISA) was used to measure t-PA levels in plasma from 34 healthy donors and 92 breast cancer patients.

Limitations

The study does not clarify the source of elevated t-PA levels in plasma.

Participant Demographics

34 healthy donors and 92 breast cancer patients, with varying tumor burdens.

Statistical Information

P-Value

p<0.01

Statistical Significance

p<0.01

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication